Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + lenalidomide + zanubrutinib + dexamethasone + cytarabine + cisplatin
- Development stage
- Phase 2
- Lead developer
- Zhejiang Province Cancer Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ZR2 + RDHAP is a sequential chemo-immunotherapy regimen being evaluated for the treatment of newly diagnosed mantle cell lymphoma (MCL). The regimen consists of an induction phase with ZR2 (rituximab, lenalidomide, and zanubrutinib) followed by RDHAP (rituximab, dexamethasone, cytarabine, and cisplatin). Rituximab is a monoclonal antibody targeting CD20; lenalidomide is an immunomodulatory agent targeting the cereblon E3 ubiquitin ligase complex; zanubrutinib is a potent, selective inhibitor of Bruton's tyrosine kinase (BTK). The RDHAP component adds dexamethasone (a corticosteroid), cytarabine (an antimetabolite), and cisplatin (a platinum-based alkylating agent) to provide intensive cytotoxic therapy. This strategy aims to achieve deep molecular remissions in MCL patients.
- Other names
- ZR2-RDHAP regimenZR-2-RDHAP regimenZR 2-RDHAP regimenZR2 followed by RDHAPZR-2 followed by RDHAPZR 2 followed by RDHAP
02
Targets
BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)DNADNA polymerase familyGR (Glucocorticoid receptor)
Beyond the preview
Go deeper on rituximab + lenalidomide + zanubrutinib + dexamethasone + cytarabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + lenalidomide + zanubrutinib + dexamethasone + cytarabine + cisplatin.